NCNorm R. C. Campbell

Norm R. C. Campbell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Norm R. C. Campbell has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 September 2011
      • Vol. 57  (9) , 997-1002

    Hypertension in people with type 2 diabetes Update on pharmacologic management

    by Norm R. C. Campbell, Richard E. Gilbert, Lawrence A. Leiter, Pierre Larochelle, Sheldon Tobe, Arun Chockalingam, Richard Ward, Dorothy Morris, Ross T. Tsuyuki, Stewart B. Harris

    Objective To summarize the evidence for the need to improve pharmacologic management of hypertension in people with type 2 diabetes and to provide expert advice on how blood pressure (BP) treatment can be improved in primary care. Sources of information Studies were obtained by performing a systematic review of the literature on hypertension and diabetes, from which management recommendations were developed, reviewed, and voted on by a group of experts selected by the Canadian Hypertension Education Program and the Canadian Diabetes Association; authors' expert opinions on optimal pharmacologic management were also considered during this process. Main message The pathogenesis of hypertension in patients with diabetes is complex, involving a range of biological and environmental factors and genetic predisposition; as a result, hypertension in people with diabetes incurs higher associated risks and adverse events. Mortality and morbidity are heightened in diabetes patients who do not achieve BP control (ie, a target value of less than 130/80 mm Hg). Large randomized controlled trials and meta-analyses of randomized controlled trials have shown that reducing BP pharmacologically is single-handedly the most effective way to reduce rates of death and disability in patients with diabetes, particularly associated cardiovascular risks. Often, combinations of 2 or more drugs (diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, angiotensin receptor blockers, calcium channel blockers, spironolactone, etc) are required for pharmacotherapy to be effective, particularly for patients in whom BP is difficult to control. However, the health care costs associated with extensively lowering BP are substantially less than the costs associated with treating the complications that can be prevented by lowering BP. Conclusion Detecting and managing hypertension in people with diabetes is one of the most effective measures to prevent adverse events, and pharmacotherapy is one of the most effective ways to maintain target BP levels in primary care.


  • Hypertension in diabetes: A call to action

    by Norman R.C. Campbell, Lawrence A. Leiter, Pierre Larochelle, Sheldon Tobe, Arun Chockalingam, Richard Ward, Dorothy Morris, Ross Tsuyuki


  • Increases in Antihypertensive Prescriptions and Reductions in Cardiovascular Events in Canada

    by Norm R.C. Campbell, Rollin Brant, Helen Johansen, Robin L. Walker, Andreas Wielgosz, Jay Onysko, Ru-Nie Gao, Christie Sambell, Stephen Phillips, Finlay A. McAlister

    The Canadian Hypertension Education Program, an extensive professional education program to improve the management of hypertension, was started in 1999. There were very large increases in diagnosis and treatment of hypertension in the first 4 years after initiation of the program. The purpose of this study was to examine the association between the changes in antihypertensive therapy with changes in hospitalization and death from major hypertension-related cardiovascular diseases in Canada between 1992 and 2003. Using various national databases, Canadian standardized yearly mortality and hospitalization rates per 1000 for stroke, heart failure, and acute myocardial infarction were calculated for individuals aged ≥20 years and regressed against antihypertensive prescription rates. Changes in rates were examined in a time series analysis. There were significant reductions ( P P P P P P =0.018 for acute myocardial infarction) were associated with the increases in antihypertensive prescriptions. This study demonstrates that the reduction in cardiovascular death and hospitalization rates is associated with an increase in antihypertensive prescriptions and that it coincides with the introduction of the Canadian Hypertension Education Program. The Canadian Hypertension Education Program educational model for improving health care could be adopted by other countries with well-developed professional and scientific societies.